Alvotech

The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab) is prescribed to treat a variety of…

Hukyndra® (adalimumab) launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in…

Increases availability of cost-effective high-concentration low-volume adalimumab in AustraliaFirst approved biosimilar from the partnership with Cipla, which also includes four other…

Alvotech hefur nú hafið eða lokið klínískum rannsóknum á fjórum líftæknilyfjahliðstæðumProlia® og Xgeva® (denosumab) eru lyf við sjúkdómum í beinum og námu tekjur af sölu þeirra um 740…

REYKJAVIK, Iceland, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients…